MassChallenge Startups Create Impact

2,928

Startups Accelerated

$8.6B

Funding Raised

$3.6B

Revenue Generated

186K+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Matricelf

Matricelf technology enables the production of autologous engineered tissue composed of scaffold and cells derived from patients biopsy.
The platform showed remarkable pre-clinical results for several medical conditions.
For its first clinical application, Matricelf focuses on spinal cord implants for patients suffering from traumatic Spinal Cord Injuries and plans to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2024.
The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of rejection.

Connect with Matricelf

Matricelf

2021

2021 Finalist IL-91

Sub industry

Therapeutics (Pharma / Biotech)

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.